300289.SHE Beijing Leadman Biochemistry Co Ltd
- Market cap
- CNY 3.27B
- P/E
- -
- P/B
- 1.95x
- ROE
- 0.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300289.SHE undervalued?
Graham numberThe Graham number of Beijing Leadman Biochemistry Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beijing Leadman Biochemistry Co Ltd fundamental analysis
No fundamental analysis for Beijing Leadman Biochemistry Co Ltd yet.
Beijing Leadman Biochemistry Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beijing Leadman Biochemistry Co Ltd
Beijing Leadman Biochemistry Co.,Ltd. researches and develops, manufactures, and sells vitro diagnostic reagents and instruments, and biochemical raw materials in the People's Republic of China. The company offers biochemical raw materials, including enzymes, antigens, coenzymes, antibodies, buffers, enzyme substrates, culture mediums, stain agents, amino acids, and other products for biotechnology, clinical diagnosis, drug development, chemical production, and other related…
Full company profileBeijing Leadman Biochemistry Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beijing Leadman Biochemistry Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 533M | 576M | 655M | 515M | 472M | 564M | 706M | 462M | 370M | 326M | 549M |
| Gross Profit | 294M | 317M | 323M | 275M | 256M | 294M | 298M | 264M | 184M | 163M | 315M |
| Operating Income | 95.6M | 117M | 72.8M | 31.4M | -7.79M | 60.2M | 7.56M | 23.9M | -73.7M | -23.5M | 37.6M |
| EBITDA | 159M | 169M | 121M | 79.8M | 40.2M | 117M | 35.1M | 84.3M | -18.3M | 31.4M | 47.9M |
| Net Income | 69.6M | 73.1M | 40.5M | 6.31M | -51.0M | 22.4M | -56.3M | 15.3M | -75.1M | -23.0M | 9.25M |
| EPS | 0.17 | 0.17 | 0.10 | 0.02 | -0.12 | 0.05 | -0.10 | 0.03 | -0.14 | -0.04 | 0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 1.66B | 1.75B | 1.73B | 1.71B | 1.63B | 2.35B | 2.00B | 1.94B | 1.82B | 1.78B | 3.57B |
| Total Liabilities | 326M | 329M | 292M | 264M | 250M | 370M | 217M | 134M | 104M | 105M | 1.45B |
| Shareholders' Equity | 1.24B | 1.31B | 1.31B | 1.32B | 1.26B | 1.84B | 1.73B | 1.74B | 1.66B | 1.64B | 1.65B |
| Cash & Short-term Investments | 200M | 305M | 270M | 296M | 353M | 929M | 799M | 855M | 890M | 566M | 575M |
| Total Debt | 150M | 166M | 117M | 56.5M | 64.0M | 79.3M | 59.1M | 4.65M | 721K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 81.8M | 121M | 81.0M | 125M | 136M | 119M | 109M | 134M | 62.4M | 29.2M | - |
| Capital Expenditure | 23.3M | 10.9M | 12.2M | 26.3M | 28.4M | 44.5M | 39.1M | 18.7M | 29.2M | 17.6M | 29.8M |
| Free Cash Flow | 58.5M | 110M | 68.8M | 98.4M | 107M | 74.6M | 69.8M | 112M | 33.2M | 11.6M | 44.5M |
| Ratios | |||||||||||
| ROE | 5.6% | 5.6% | 3.1% | 0.5% | -4.0% | 1.2% | -3.3% | 0.9% | -4.5% | -1.4% | 0.6% |
| ROA | 4.2% | 4.2% | 2.3% | 0.4% | -3.1% | 1.0% | -2.8% | 0.8% | -4.1% | -1.3% | 0.3% |
| Net Profit Margin | 13.1% | 12.7% | 6.2% | 1.2% | -10.8% | 4.0% | -8.0% | 3.3% | -20.3% | -7.0% | 1.7% |
| Debt to Equity | 0.12x | 0.13x | 0.09x | 0.04x | 0.05x | 0.04x | 0.03x | 0.00x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Beijing Leadman Biochemistry Co Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 17, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | CNY 5.44M | 0.01 | - |
| 2023 | CNY 201K | 0.00 | 1.3% |
| 2022 | CNY 10.9M | 0.02 | - |
| 2021 | CNY 403K | 0.00 | 1.8% |
| 2020 | CNY 4.18M | 0.01 | - |
| 2019 | CNY 5.78M | 0.02 | 91.7% |
| 2018 | CNY 19.0M | 0.05 | 46.9% |
| 2017 | CNY 24.0M | 0.06 | 32.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 25:10 on Oct 27, 2015.
Who owns Beijing Leadman Biochemistry Co Ltd
- Insiders 50.73%
- Institutions 0.57%
- Public & others 48.71%
- Shares outstanding 544M
- Free float 291M
Beijing Leadman Biochemistry Co Ltd company profile
- Company name
- Beijing Leadman Biochemistry Co Ltd
- Ticker
- 300289.SHE
- ISIN
- CNE100001C22
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Feb 16, 2012
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 420
- Fiscal year end
- December
- Address
- No.5 Xinghai Road, Beijing, China, 100176
- Phone
- 86 10 6785 5500
- Website
- leadmanbio.com
About Beijing Leadman Biochemistry Co Ltd
Beijing Leadman Biochemistry Co.,Ltd. researches and develops, manufactures, and sells vitro diagnostic reagents and instruments, and biochemical raw materials in the People's Republic of China. The company offers biochemical raw materials, including enzymes, antigens, coenzymes, antibodies, buffers, enzyme substrates, culture mediums, stain agents, amino acids, and other products for biotechnology, clinical diagnosis, drug development, chemical production, and other related applications. It also provides biochemical reagents for liver function, lipid profile, diabetes reagents, pancreas function, tumor detection, protein and others, multi calibrators and multi co, semi-quantitative assays, coagulation reagents, cardiac marker, cardiac reagents, electrolytes, and renal function; companion reagents regents for tumor, thyroid hormone, sex hormone, infectious disease, and others; and IDS-compatible luminescent reagents. In addition, it offers testing instruments. Beijing Leadman Biochemistry Co.,Ltd. was founded in 1997 and is based in Beijing, the People's Republic of China.
Beijing Leadman Biochemistry Co Ltd management
5- Mr. Ouyang XuHead of Finance & Accounting Supoervisor · born 1984
- Mr. Yaoliang DingVice President · born 1975
- Ms. Li Hua ZhangVP & Secretary · born 1979
- Lan Zhen WangTechnical Director
- Mr. Kun ZhangDirector of Human Resources & Administrative Center · born 1971